Iniparib (Breast Cancer) Analysis and Forecasts to 2020


#97925

45pages

GlobalData

$ 2000

In Stock

 


GlobalDatas pharmaceuticals report, Iniparib (Breast cancer) - Analysis and Forecasts to 2020 provides Iniparib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

 

 

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Iniparib including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Iniparib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts from 2015-2020 for Iniparib in the seven major markets


Reasons to buy

 

 

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets


Keywords

Iniparib , BSI-201, poly (ADP-ribose) polymerase, PARP1, BiPar Sciences, Sanofi-Aventis, gemcitabine/carboplatin, Phase III clinical trials

 

 

Table of Contents

 

1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 4


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Hormone Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8


3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 Breast Cancer: Most Frequent Cancer in Women 10
3.3.2 Increasing Breast Cancer Incidence Rate 10
3.3.3 Decreasing Breast Cancer Mortality Rate 12
3.3.4 High Survival Rates of Breast Cancer 14


4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15


5 Predictive Biomarker in the Treatment of Breast Cancer 17


6 Treatment Options of Breast Cancer 19
6.1 Stage 0 Breast Cancer 19
6.2 Early Stage Breast Cancer (Excluding Stage 0) 20
6.3 Metastatic Breast Cancer (MBC) 22
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 22
6.3.2 Cytotoxic Chemotherapy 24
6.3.3 Management of Patients with HER-2 Positive Patients 26


7 Iniparib (BSI-201) 28
7.1 Introduction 28
7.2 Mechanism of Action 28
7.3 Clinical Studies of Iniparib 28
7.4 Factors Affecting Sales of Iniparib 29
7.4.1 New Class Drug 29
7.4.2 Low Competition from Branded Marketed Drugs 29
7.4.3 Low Relative Efficacy 29
7.4.4 Low Safety 29
7.5 Drug Evaluation 30
7.5.1 Drug Risk Benefit Score 30
7.5.2 Intensity of Competition 31
7.6 Sales Forecasts 31
7.6.1 Target Patient Pool of Iniparib 31
7.6.2 Dosing 32
7.6.3 Market Penetration 32
7.6.4 Annual Cost of Therapy 32
7.6.5 Sales Projections of Iniparib 33


8 Breast Cancer Market: Appendix 42
8.1 Market Definitions 42
8.2 Abberiviations 42
8.3 Research Methodology 42
8.3.1 Coverage 43
8.3.2 Secondary Research 43
8.3.3 Forecasting 43
8.3.4 Number of Patients Approved to Take the Drug 43
8.3.5 Net Penetration of Drug 44
8.3.6 Net Annual Dosing 44
8.3.7 Annual Cost of Therapy 44
8.4 Drug Sales Estimates Model 44
8.5 Contact Us 45
8.6 Disclaimer 45
8.7 Sources 45


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14
Table 3: Efficacy of Iniparib with Chemotherapy vs Chemotherapy Alone 29
Table 4: Drug Risk Benefit Score of Iniparib in Second-line treatment of Breast Cancer 30
Table 5: Iniparib, Breast Cancer, Global, Sales Estimates ($m), 20152020 33
Table 6: Iniparib, Breast Cancer, the US, Sales Estimates ($m), 20152020 34
Table 7: Iniparib, Breast Cancer, the UK, Sales Estimates ($m), 20152020 35
Table 8: Iniparib, Breast Cancer, France, Sales Estimates ($m), 20152020 36
Table 9: Iniparib, Breast Cancer, Germany, Sales Estimates ($m), 20152020 37
Table 10: Iniparib, Breast Cancer, Italy, Sales Estimates ($m), 20152020 38
Table 11: Iniparib, Breast Cancer, Spain, Sales Estimates ($m), 20152020 39
Table 12: Iniparib, Breast Cancer, Japan, Sales Estimates ($m), 20172020 40


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 17: Treatment Options, DCIS Breast Cancer 19
Figure 18: Treatment Options, LCIS Breast Cancer 20
Figure 19: Classification of Stages I, II and IIIA 20
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 27: Drug Model Diagram of Iniparib 31
Figure 28: Iniparib, Breast Cancer, Global, Sales Estimates ($m), 20152020 33
Figure 29: Iniparib, Breast Cancer, the US, Sales Estimates ($m), 20152020 34
Figure 30: Iniparib, Breast Cancer, the UK, Sales Estimates ($m), 20152020 35
Figure 31: Iniparib, Breast Cancer, France, Sales Estimates ($m), 20152020 36
Figure 32: Iniparib, Breast Cancer, Germany, Sales Estimates ($m), 20152020 37
Figure 33: Iniparib, Breast Cancer, Italy, Sales Estimates ($m), 20152020 38
Figure 34: Iniparib, Breast Cancer, Spain, Sales Estimates ($m), 20152020 39
Figure 35: Iniparib, Breast Cancer, Japan, Sales Estimates ($m), 20172020 40
Figure 36: Iniparib, Breast Cancer, Global, Sales Distribution by Country (%), 2020 41
Figure 37: Patients Approved for the Drug 44